NASDAQ: HLVXHillevax Inc Stock
$2.10+0.01 (+0.48%)
Updated Sep 15, 2025
HLVX Price
$2.10
Fair Value Price
$2.64
Market Cap
$105.30M
52 Week Low
$1.34
52 Week High
$2.17
P/E
-1.46x
P/B
0.71x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$71.10M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.18
Operating Cash Flow
-$60M
Beta
1.08
Next Earnings
Nov 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
HLVX Overview
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. Founded as MokshaCo, Inc. in 2020, the company changed its name in 2021. HilleVax is headquartered in Boston, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HLVX's potential to beat the market
- HLVX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
HLVX
RankedUnranked of 478
RankedUnranked of 478
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.40 | A | |
| $37.30 | A | |
| $7.70 | A |
Be the first to know about important HLVX news, forecast changes, insider trades & much more!
HLVX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HLVX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HLVX ($2.10) is undervalued by 20.57% relative to our estimate of its Fair Value price of $2.64 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
HLVX ($2.10) is significantly undervalued by 20.57% relative to our estimate of its Fair Value price of $2.64 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
HLVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HLVX due diligence checks available for Premium users.
Valuation
HLVX fair value
Fair Value of HLVX stock based on Discounted Cash Flow (DCF)
Price
$2.10
Fair Value
$2.64
Undervalued by
20.57%
HLVX ($2.10) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HLVX ($2.10) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HLVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HLVX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.46x
Industry
-100.7x
Market
37.32x
HLVX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.71x
Industry
4.65x
HLVX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HLVX's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.3M
Profit Margin
0%
HLVX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$174.9M
Liabilities
$27.1M
Debt to equity
0.18
HLVX's short-term assets ($162.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HLVX's short-term assets ($162.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HLVX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$789.0k
Investing
$12.0M
Financing
$0.0
HLVX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HLVX vs Biotech Stocks
Hillevax Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.